BeBetter Med Inc.

BeBetter Med Inc. is a biotechnology company specializing in the research and development of innovative pharmaceuticals, with a strong emphasis on oncology and the treatment of severe diseases. Established in 2012 by scientists with international backgrounds, the company has built a diverse clinical pipeline comprising both small molecule and RNA-based therapeutics targeting cancers, autoimmune disorders, and metabolic diseases. Noteworthy developments include first-in-class compounds such as BEBT-908, a PI3K/HDAC dual inhibitor for refractory lymphomas, and BEBT-109, a pan-EGFR inhibitor undergoing advanced clinical trials for solid tumors. Through its US-based subsidiary, BeBetter Pharma, the company is advancing next-generation siRNA therapy platforms, including technologies for targeted delivery to renal and hepatic tissues. BeBetter Med Inc. collaborates globally to co-develop, license, and commercialize its therapeutic candidates, aiming to address unmet medical needs and expand the frontiers of precision medicine. The company’s innovative approach and robust R&D capabilities have positioned it as a prominent player in China’s biopharmaceutical industry, contributing significantly to the development of novel treatments in both domestic and international markets.